MELBOURNE, Australia, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced that the US Patent and Trademark Office (USPTO) has granted a key patent covering medication adherence monitoring devices that include an optical dose counter.
The issue of the U.S. Patent No. 9,468,729 on 18 October 2016 further strengthens the Company’s growing intellectual property portfolio.
This US patent is the first to be issued in a planned suite of patents related to medication adherence monitoring devices that include an optical dose counter. The optical dose counter allows the device to determine when a dose of medication is being dispensed. Through its SmartInhaler™ technology, Adherium pioneered the use of add-on adherence monitoring devices with external optical dose counters. This patent confirms Adherium’s ongoing commitment to innovation in the medication adherence market.
Adherium’s Group CEO, Garth Sutherland said, “Adherium is committed to improving patient health outcomes through accurate medication monitoring and invests significant effort and resources into Research & Development to achieve this objective. As a result, Adherium intends to diligently assert its intellectual property rights.”
Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.
Adherium operates globally from bases in the USA, Europe and Australasia.
Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. The Company’s proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.
The Smartinhaler™ platform has so far been used in more than 65 projects (clinical, device validation or other) and has been referenced in 56 peer reviewed journal articles. Clinical outcomes data has proven that the Smartinhaler™ platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults, leading to improved quality-of-life and demonstrating a substantial gain over current best practice treatment. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.
|At Adherium:|| |
Head of Corporate Development
M: +64 27 807 8153
| North America|
Senior Vice President, Business Development, North America
M: +1 610 955 5886
|Media enquiries:|| |
|Australia and New Zealand|
D: +61 3 9620 3333
|North America |
Erich A. Sandoval
D: +1 213-908-6226
M: +1 917-497-2867
D: +44 20 7866 7863